InvestorsHub Logo
Followers 36
Posts 2689
Boards Moderated 0
Alias Born 06/09/2011

Re: None

Thursday, 05/26/2022 6:12:44 AM

Thursday, May 26, 2022 6:12:44 AM

Post# of 688721
We respond to “promising” survival data from phase III trial of DCVax®-L
We respond to preliminary overall survival data from phase III clinical trial that suggests DCVax-L may help extend survival for patients with newly-diagnosed or recurrent glioblastomas.

Thursday 26 May 2022

By Glenn Saitch

https://www.thebraintumourcharity.org/media-centre/news/research-news/we-respond-to-promising-survival-data-from-phase-iii-trial-of-dcvax-l/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News